Zoetis Inc. ZTS
83.02 USD +0.45 (+0.54%)
Nov 12, 2026, 1:38 PM EST
82.48 Day range 83.84
69.10 52-week range 131.10
- YTD
- -34.02%
- 1 year
- -31.53%
News
zacks.com Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.
businesswire.com Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
businesswire.com Zoetis to Participate in the Jefferies Global Healthcare Conference in London PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a…
zacks.com ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.
marketbeat.com What Zoetis (ZTS) Said on Its Q3 Earnings Call Zoetis NYSE: ZTS reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal…
seekingalpha.com Zoetis: Quality Company Trading Cheap Zoetis Inc., formerly Pfizer's veterinary arm, is a global leader in animal pharmaceuticals and diagnostics. ZTS generates most revenue from companion animal products, with approximately 30% from…
seekingalpha.com Zoetis Inc. (ZTS) Q3 2026 Earnings Call Transcript Zoetis Inc. ( ZTS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Mathieu Aussermeier Kristin Peck - CEO & Director James Saccaro - Executive VP, CFO & COO Conference Call…
fool.com Zoetis: 3 Key Takeaways for Long-Term Investors Zoetis's organic operational revenue fell 1% in the third quarter. Global livestock revenue rose 7% to $797 million.
benzinga.com Republican Senator Who Won Reelection Is Selling Magnificent Seven Stocks: Here Are the Trades Sen. Shelley Moore Capito, who won reelection, sold shares of Apple, Meta and Microsoft weeks before the midterms. Here are the trades.
zacks.com ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.
reuters.com Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall
benzinga.com Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy Zoetis Inc. (NYSE:ZTS) reported third-quarter adjusted earnings of $1.75 per share, beating the consensus of $1.51.
benzinga.com Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy Zoetis beats Q3 earnings and revenue estimates, lifts full-year 2026 guidance, and balances pet care affordability pressures with steady livestock gains.
zacks.com Zoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Zoetis Q3 2026 Earnings Call Transcript Zoetis (NYSE:ZTS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates Zoetis (ZTS) came out with quarterly earnings of $1.75 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.7 per share a year ago.
benzinga.com Zoetis Raises FY2026 Adj EPS Guidance from $6.15-$6.25 to $6.25-$6.35 vs $6.28 Est; Raises FY2026 Sales Guidance from $9.120B-$9.320B to $9.220B-$9.320B vs $9.326B Est Zoetis (NYSE:ZTS) raises FY2026 Adj EPS guidance from $6.15-$6.25 to $6.25-$6.35 vs $6.28 analyst estimate. Raises FY2026 sales outlook from $9.120 billion-$9.320 billion to $9.220 billion-$9.320…
benzinga.com Zoetis Q3 Adj. EPS $1.75 Beats $1.51 Estimate, Sales $2.391B Beat $2.304B Estimate Zoetis (NYSE:ZTS) reported quarterly earnings of $1.75 per share which beat the analyst consensus estimate of $1.51 by 15.89 percent. This is a 2.94 percent increase over earnings of $1.70 per share…
businesswire.com Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. "Our…
benzinga.com Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $82 Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $85 to $82.- benzinga.com UBS Maintains Neutral on Zoetis, Raises Price Target to $85 UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and raises the price target from $80 to $85.
benzinga.com This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Werner, Zoetis, Apple, Heartland Express and Elanco, cutting ratings to Neutral/Hold and lowering price targets.- benzinga.com Jefferies Downgrades Zoetis to Hold, Lowers Price Target to $83 Jefferies analyst Keith Devas downgrades Zoetis (NYSE:ZTS) from Buy to Hold and lowers the price target from $103 to $83.
benzinga.com Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74 Goldman Sachs analyst Matt Dellatorre initiates coverage on Zoetis (NYSE:ZTS) with a Neutral rating and announces Price Target of $74.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Zoetis (NYSE:ZTS) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Stifel Maintains Hold on Zoetis, Lowers Price Target to $80 Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $85 to $80.- benzinga.com FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies
benzinga.com BNP Paribas Maintains Outperform on Zoetis, Lowers Price Target to $110 BNP Paribas analyst Navann Ty maintains Zoetis (NYSE:ZTS) with a Outperform and lowers the price target from $146 to $110.- benzinga.com Piper Sandler Maintains Neutral on Zoetis, Lowers Price Target to $80 Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $90 to $80.
benzinga.com 5 Stock Picks Last Week From Wall Street's Most Accurate Analysts U.S. stocks close higher on Friday, with Nasdaq up 300 points and S&P 500 at record high. Benzinga's Analyst Ratings API can aid in stock picks.
benzinga.com UBS Maintains Neutral on Zoetis, Lowers Price Target to $80 UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $85 to $80.- benzinga.com JP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $115 JP Morgan analyst Chris Schott maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $130 to $115.
benzinga.com Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds Zoetis beat second-quarter earnings estimates but missed on revenue, cut 2026 guidance and cited weaker pet health demand and pricing pressure.- benzinga.com Zoetis Lowers FY2026 Adj EPS Guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 Est; Lowers FY2026 Sales Guidance from $9.680B-$9.960B to $9.120B-$9.320B vs $9.726B Est Zoetis (NYSE:ZTS) lowers FY2026 Adj EPS guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 analyst estimate. Lowers FY2026 sales outlook from $9.680 billion-$9.960 billion to $9.120 billion-$9.320…
- benzinga.com Zoetis Q2 Adj. EPS $1.87 Beats $1.86 Estimate, Sales $2.468B Miss $2.502B Estimate Zoetis (NYSE:ZTS) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.86 by 0.54 percent. This is a 6.25 percent increase over earnings of $1.76 per share…
benzinga.com Michael Burry Expands Bets Against Nvidia, Micron— and Is Now Buying Lululemon and DraftKings Michael Burry expands short positions against Nvidia and AI, while piling into de-risked value stocks like Lululemon and DraftKings.- benzinga.com UBS Maintains Neutral on Zoetis, Lowers Price Target to $85 UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $99 to $85.
- benzinga.com Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $99 Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $115 to $99.
- benzinga.com Zoetis Commercially Rolls Out Portela In Canada, EU To Treat Pain Associated With Osteoarthritis Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor…
benzinga.com Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia The Australian agency is conducting a Phase 2 assessment of Zoetis' $160 million acquisition of Neogen's genomics unit due to competition concerns.
benzinga.com Recent Report Shows That Rep. Byron Donalds Sold Up to $60K Worth of Cadence Design Systems Stock July 15, 2026 records indicate that Representative Byron Donalds filed a sale of Cadence Design Systems (NASDAQ:CDNS), valued between $4,004 and $60,000. According to the July filing, the transaction…- benzinga.com Zoetis Inks Agreement To Acquire Veterinary Teleradiology Services Platform VitalRADS; Financial Terms Undisclosed Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this…
- benzinga.com Zoetis Announces EC Grants Marketing Authorization For Poulvac Procerta HVT-ND, Recombinant Vector Vaccine For Protection Of Chickens Against Newcastle Disease And Marek’s Disease Viruses Recombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a single doseZoetis Inc. (NYSE:ZTS) today announced that the European Commission (EC) has granted…
- benzinga.com Barclays Maintains Equal-Weight on Zoetis, Lowers Price Target to $85 Barclays analyst Glen Santangelo maintains Zoetis (NYSE:ZTS) with a Equal-Weight and lowers the price target from $136 to $85.
- benzinga.com TD Cowen Maintains Buy on Zoetis, Lowers Price Target to $104 TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $150 to $104.
benzinga.com Stifel Maintains Hold on Zoetis, Lowers Price Target to $85 Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $95 to $85.
benzinga.com Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick Cramer says Zoetis has issues. Prefers this stock in animal health industry. Energy Transfer is in a good position.- benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session